ATHENS, Greece — Two strategies under investigation suggest that manipulating the gut microbiome could improve the effectiveness of immunotherapy in patients with melanoma, according to new research presented at the 11th World Congress of Melanoma (WCM) and 21st EADO Congress 2025.
Health Professionals
HOPA 2025: Advancements and Challenges in Neoadjuvant Therapy for Regional Melanoma
Christine Barrett, PharmD, BCOP, addressed advances in the treatment of stage III melanoma that provide the potential to improve long-term outcomes by enhancing immune response, tailoring surgical approaches, and refining patient selection strategies.
What Role May ctDNA Have in Melanoma Management?
Circulating tumor DNA (ctDNA) negativity has been associated with prolonged response to treatment with immune checkpoint inhibitors (ICIs), researchers have found. While it is still too early for ctDNA to play a role in clinical practice, experts expressed enthusiasm for the future.
Pharmacists Play Key Role in Managing Toxicity During Neoadjuvant Therapy for Melanoma
In a Pharmacy Times interview at the HOPA Annual Meeting 2025, Christine Barrett, PharmD, BCOP, clinical pharmacy specialist at West Virginia University, discussed the advantages of neoadjuvant therapy in melanoma, particularly the use of immunotherapy to leverage the tumor microenvironment and existing T-cell populations before surgery.